Inventia Healthcare Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Inventia Healthcare Limited - overview
Established
1985
Location
Mumbai, Maharashtra, India
Primary Industry
Pharmaceuticals
About
Inventia Healthcare Limited, based in India, specializes in the development and supply of innovative pharmaceutical products designed to improve treatment outcomes in various therapeutic areas. Founded in 1985, Inventia Healthcare Limited is a Mumbai-based company focused on pharmaceutical innovation. The firm has undergone strategic adjustments over the years, expanding its operations to meet global healthcare demands. As part of its current structure, on July 1, 2024, Platinum Equity acquired a 75% majority stake for approximately INR 25 billion from InvAscent Capital Partners and Jacob Ballas Capital.
The company has successfully completed 3 deals to date, raising a total of INR 25 billion with the latest funding being a Secondary Buyout. Inventia Healthcare specializes in delivering innovative pharmaceutical products aimed at enhancing treatment outcomes across various therapeutic areas. The company’s core offerings include advanced formulations and drug delivery systems designed to meet unmet medical needs in patient care. Their products target a diverse client base, including hospitals and pharmacies, ensuring accessibility for patients requiring chronic disease management and acute care solutions.
The company's products are marketed in regions including North America, Europe, and parts of Asia. In 2018, Inventia Healthcare reported revenue of INR 47,976,515. 60 and an EBITDA of INR 6,948,358. 30.
The company's revenue generation is facilitated through B2B partnerships and direct sales to healthcare institutions, with products marketed under specific brand names. Pricing strategies are established via negotiated contracts that align with the needs of healthcare providers and ensure a reliable supply of pharmaceutical products. Looking ahead, Inventia Healthcare plans to launch several new products designed to enhance medication delivery and patient compliance in 2025. The company aims to expand its market presence further into Europe and Southeast Asia by 2026, leveraging recent funding to support these initiatives.
The capital raised from the Secondary Buyout will be utilized to enhance R&D capabilities and facilitate entry into these new markets, ensuring that Inventia continues to address evolving healthcare needs.
Current Investors
InvAscent Capital Partners, Jacob Ballas Capital
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.inventiahealthcare.com/
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Inventia Healthcare Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | Inventia Healthcare Limited | - | ||||||||
| Growth | Completed | Inventia Healthcare Limited | - | ||||||||
| Growth | Completed | Inventia Healthcare Limited | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.